Fulgent Genetics, Inc. (FLGT) released Loss for fourth quarter of -$5.888 million
The company's bottom line came in at -$5.888 million, or -$0.19 per share. This compares with -$128.149 million, or -$4.30 per share, last year.
The company's revenue for the period rose 8.1% to $76.214 million from $70.505 million last year.
Fulgent Genetics, Inc. earnings at a glance (GAAP) :
-Earnings: -$5.888 Mln. vs. -$128.149 Mln. last year.
-EPS: -$0.19 vs. -$4.30 last year.
-Revenue: $76.214 Mln vs. $70.505 Mln last year.
Excluding items, for the fourth quarter, the company recorded a profit of $1.163 million, or $0.04 per share, lesser than $8.269 million, or $0.28 per share, posted for the same period last year.
Looking ahead, for the full-year 2025, the company expects a wider net loss. However, it anticipates an increase in core revenue.
Fulgent expects a net loss of 1.95 per share, with an adjusted loss of around $0.65 per share. On average, three analysts polled expect the firm to report a loss of $0.46 per share for the year. Analysts’ estimates typically exclude special items.
Annual core revenue is expected to be around $310 million, below analysts’ forecast of $324.21 million.
For the full-year 2024, the company has recorded a net loss per share of $1.41 per share, with adjusted earnings per share of $0.49, on core revenue of $281.2 million.
For comments and feedback: editorial@rttnews.com